<DOC>
	<DOCNO>NCT03101735</DOCNO>
	<brief_summary>This non interventional , multicenter clinical trial , adult patient receive Tecfidera per approve SmPC routine clinical practice . The primary objective study evaluate total societal cost healthcare system relate use Tecfidera RRMS patient . The study capture data simple matter easily interpret provide advantage country effort market access arena infancy . For aforementioned reason , propose study may prove quite valuable support DMF cost‐effective therapy , valuable patient public health care system well , provide necessary information evaluation need examine regard positive reimbursement list future decision .</brief_summary>
	<brief_title>Study Assess Resource Utilization Quality Life Patients With RRMS Treated With Tecfidera Greece</brief_title>
	<detailed_description>The study take place Greece . Investigators participate broad geographical distribution order ensure proper representation area Greece . Investigator 's decision prescribe DMF ( Tecfidera® ) ( accord indication treatment define summary product characteristic , SmPC current clinical practice ) , precede entry study .</detailed_description>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Persons age 1865 year . Patients confirm diagnosis RRMS . Patients decision prescribe therapy Tecfidera® , accord locally approve product 's summary product characteristic ( SmPC ) already take prior enrolment study . The assignment patient therapeutic strategy decide advance , fall within current practice , prescription Tecfidera® clearly separate physician 's decision include patient current study . Patients must sign informed consent document . Patients must able read , understand complete study specific questionnaire . Patients forms MS , like Clinically Isolated Syndrome ( CIS ) progressive form . Patients initiated treatment Tecfidera® 7 day study enrolment receive DMF different time prior period . Patients meet contraindication administration study drug accord approve SmPC . Receipt investigational agent within 30 day 5 halflives investigational agent ( whichever longer ) commencement therapy Tecfidera® .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>